Latest News on Avandia: German Study Adds More Reasons to Avoid it
July 12, 2007--In the latest news on Avandia, a review by German researchers
indicates that little evidence supports using Avandia (rosiglitazone) to improve
the quality or length of life among adults with diabetes.
The review
appears in the latest issue of the Cochrane Collaboration, a publication
of the Cochrane Collaboration, an international organization that evaluates
medical research.
The authors pooled data from 18 randomized controlled
trials including more than 8,000 participants. About half of the patients took
Avandia and the other received either an alternative medication or a placebo.
The data suggest that the drug might worsen complications of the disease
such as bone fractures and heart disease. The review supports findings from an
analysis of studies, published in May, which reported an increased risk of death
from cardiovascular causes in patients taking the medication.
If you or a
loved one has suffered cardiac complications after ingesting Avandia, you
deserve the guidance of an experienced drug attorney. Get a free case review by
filling out the form below.
see also:
Study Reveals Risks, 6.6.07
Study Designed to Debunk Risks Raises Questions About Avandia MedicineAvandia Medicine Still Has Serious Heart Risks, Doctors Warn
FDA Approval of Avandia
FDA Approval of Avandia, Drug Treatment for Type 2 DiabetesHistory and Approval Process for Diabetes Med Avandia--FDA Information
News & Warnings
Avandia Breaking News: Glaxo Warned in 2001 about Misleading MarketingBloomberg News: FDA Warned Glaxo about Avandia Marketing in 2001
